The critical issue is that the initial cellular morphology at the time of EGF administration frequently differs significantly from that at the end of the measurement protocol, introducing a significant source of error in cancer diagnostic applications that rely on precise capacitance measurements. This evidence concerns the gene EGF and cancer.